- This is the first of a family of critical Alzheimer's Disease biomarker assays to be released by Biosensis for neurological disease research.
- Biosensis retains exclusive worldwide rights for MOAB-2 based immnoassays.
Biosensis' oAβ ELISA has recently been published in the below papers:
Combes M, et al. (2014) "Glutamate protects neuromuscular junctions from deleterious effects of β-amyloid peptide and conversely: An in vitro study in a nerve-muscle coculture." J Neurosci Res. 93(4):633-43, PMID: 25491262. Species: Rat neurites & human muscle cell co-culture supernatants.
Liu Y, et al. (2014) "IKKbeta Deficiency in Myeloid Cells Ameliorates Alzheimer's Disease-Related Symptoms and Pathology." J Neurosci. 34(39):12982-99, PMID: 25253847. Species: Transgenic Mouse brain lysates.
Tai LM, et al. (2014) "Amyloid-β Pathology and APOE Genotype Modulate Retinoid X Receptor Agonist Activity in vivo." J Biol Chem. 289(44):30538-55, PMID: 25217640. Species: EFAD-Tg mice.
Seo Dong Han, et al. (2015) "Plasma-enabled sustainable elemental lifecycles: honeycomb-derived graphenes for next-generation biosensors and supercapacitors." Green Chem. 17, 2164-2171. Species: Synthetic constructs.
Biosensis' MOAB-2 monoclonal antibody has recently been published in the below papers:
Iulita MF, et al. (2014) "Intracellular Aβ pathology and early cognitive impairments in a transgenic rat model overexpressing human amyloid precursor protein: a multidimensional study." Acta Neuropathol Commun. 2:61, PMID: 24903713. Application: IF, IH
Smith BR, et al. (2014) "Neuronal inclusions of alpha-synuclein contribute to the pathogenesis of Krabbe disease." J Pathol. 232(5):509-21, PMID: 24415155. Application: IF
Condello C, et al. (2015) "Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques." Nat Commun. 6:6176, PMID: 25630253. Application: IF